Milrinone
8,084 views
Cardiovascular Pharm (Old)
- Adenosine
- Magnesium
- Nitroprusside
- Nitrates
- Ivabradine
- Digoxin/Digitalis
- Class IA Antiarrhythmics
- Class IB Antiarrhythmics
- Class IC Antiarrhythmics
- Class II Antiarrhythmics
- Class III Antiarrhythmics - Amiodarone
- Class III Antiarrythmics - Sotalol
- Class III Antiarrhythmics - Ibutilide, Dofetilide
- Class IV Antiarrhythmics - Verapamil, Diltiazem
- HMG-CoA Reductase Inhibitors (Statins)
- Ezetimibe
- Fibrates
- PCSK9 Inhibitors (Alirocumab, Evolocumab)
- Fish Oil and Omega-3s
- Milrinone
- Aliskiren
- Hydralazine
- Ranolazine
- Sacubitril
Summary
Milrinone is a selective PDE-3 inhibitor used for short-term treatment of acute heart failure. By blocking PDE3, milrinone increases cAMP levels in the heart, which leads to increased contractility. Milrinone’s inhibition of PDE3 also affects the blood vessels to cause vasodilation. This can result in the adverse effect of hypotension.
Key Points
- Milrinone
- Mechanism
- Selective PDE3 inhibitor
- Prevents PDE-mediated degradation of of cAMP
- Selective PDE3 inhibitor
- Clinical Use
- Acute decompensated heart failure
- Increased cAMP in cardiomyocytes causes Ca2+ influx
- Increases contractility (ionotropy) and heart rate (chronotropy)
- Pulmonary arterial hypertension (PAH)
- Acute decompensated heart failure
- Adverse Effects
- Arrhythmias
- Hypotension
- In vascular smooth muscle, increase in cAMP induces vasodilation, causing decreased SVR and decreased BP
- Mechanism